• Explore /
  • Poster
  • / The R0 resection rate after neoadjuvant bevacizumab (Bev) plus DOF versus DOF in local advanced gastric carcinoma (LAGC) and its association with circulating tumor cell (CTC).

The R0 resection rate after neoadjuvant bevacizumab (Bev) plus DOF versus DOF in local advanced gastric carcinoma (LAGC) and its association with circulating tumor cell (CTC).

Abstract Poster

Authors

null

Nan Du

Department of Oncology, First Affiliated Hospital, Chinese PLA General Hospital, Beijing, China

Nan Du , Junxun Ma , Shan Wang , Xiaosong Li , Junzhong Sun , Huanrong Kang , Yan Fu , Hui Zhao , Yi Hu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 4043)

DOI

10.1200/jco.2014.32.15_suppl.4043

Abstract #

4043

Poster Bd #

130

Abstract Disclosures

Similar Posters

First Author: Hongli Li

First Author: Claudia Pauligk

First Author: Jian Xiao

First Author: Takako Yoshii